drugset / Trial / NCT06279286
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
RandomizedSequentialDouble-blindTreatment
Summary
The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.
Timeline
- Start
- 2024-05
- Primary completion
- 2025-01
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10506 | Unknown | 10 mg | — |
| Subject | HS-10506 | Unknown | 20 mg | — |
| Subject | HS-10506 | Unknown | 40 mg | — |
| Subject | HS-10506 | Unknown | 80 mg | — |